Lucid Diagnostics Reports Q1 2026 Results and Outlook

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Lucid Diagnostics ( (LUCD) ) has issued an announcement. On May 14, 2026, Lucid Diagnostics reported first-quarter 2026 results and a business update, highlighting 3,177 EsoGuard tests processed and $1.3 million in related revenue for the quarter ended March 31, 2026. The company stressed that securing Medicare coverage for EsoGuard remains its key milestone as it builds demand through targeted outreach to Medicare and VA populations and expanded engagement with health systems and commercial insurers. Lucid strengthened its balance sheet with an underwritten public offering that generated about $17 million in net proceeds, ending the quarter with $45 million in pro forma cash and an expected runway into 2027. Despite posting a GAAP net loss attributable to common stockholders of $23.6 million and a non-GAAP adjusted loss of $10.5 million, management pointed to a strong presence at Digestive Disease Week and an anticipated clinical guideline update recommending EsoGuard and EsoCheck as important factors that could accelerate adoption and improve its longer-term commercial outlook. The most recent analyst rating on (LUCD) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page. Spark’s Take on LUCD Stock According to Spark, TipRanks’ AI Analyst, LUCD is a Neutral. The score is held down primarily by weak financial performance (structurally negative margins, rising leverage, and heavy cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting factors include improving commercial traction and payer/VA progress from the earnings call, plus added liquidity from the recent equity raise, though both are tempered by reimbursement timing and dilution risk. To see Spark’s full report on LUCD stock, click here. More about Lucid Diagnostics Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., is a commercial-stage cancer prevention medical diagnostics company focused on esophageal disease. Its primary products include the EsoGuard Esophageal DNA Test and the EsoCheck device, targeting early detection of conditions that can lead to esophageal cancer, with a growing emphasis on Medicare, VA, health system and commercial payor adoption. Average Trading Volume: 754,110 Technical Sentiment Signal: Sell Current Market Cap: $184.3M For a thorough assessment of LUCD stock, go to TipRanks’ Stock Analysis page.